What do you do when you’re told you have one of the deadliest forms of brain cancer?
For Australian cancer expert Richard Scolyer, the answer was simple: fight back — and help science along the way.
Scolyer, who has died at 59, became known around the world after volunteering as the first patient to receive an experimental treatment for glioblastoma.
It was based on his own groundbreaking cancer research.
Diagnosed in 2023, he refused to accept what many saw as an inevitable outcome.
“It didn’t sit right with me… to just accept certain death without trying something,” he once said.
Working alongside his close friend and fellow researcher, Georgina Long, Scolyer underwent a pioneering immunotherapy approach before surgery.
Cancer Pioneer Leaves Lasting Legacy
A strategy that had already transformed outcomes for advanced melanoma patients.
Their work helped turn a disease once considered a death sentence into one where many patients now survive long term.
The treatment’s promising results have since inspired a clinical trial in the United States, offering hope to future brain cancer patients.
Even in his final letter, Scolyer remained focused on helping others.
“We can and should continue to push boundaries,” he wrote, urging scientists to stay bold and governments to back innovation.
His life leaves behind more than scientific breakthroughs.
It leaves a powerful reminder that sometimes the bravest experiment is believing there might be a better answer.
